Table 1 Distribution of cytokines scores at the start of treatment by autoantibodies
From: Biologic predictors of clinical improvement in rituximab-treated refractory myositis
Baseline | Anti-synthetase | TIF | SRP | MJ | MI-2 | Other AutoAb | No AutoAb | Undefined | P value |
|---|---|---|---|---|---|---|---|---|---|
(N = 28) | (N = 19) | (N = 21) | (N = 18) | (N = 25) | (N = 24) | (N = 33) | (N = 9) | ||
IFNCKa | 43.3 | 30.9 | 11.8 | 18.7 | 29.9 | 21.2 | 13.4 | 23.2 | <.001 |
(1.4, 100.0) | (7.9, 85.9) | (1.9, 49.3) | (4.1, 66.2) | (5.0, 87.2) | (2.9, 85.7) | (2.5, 72.1) | (5.7, 65.4) | ||
TH1 | 27.9 | 23.3 | 19.6 | 21.9 | 21.8 | 26.4 | 20.7 | 22.2 | 0.070 |
(6.1, 80.5) | (13.5, 77.1) | (9.5, 88.9) | (3.8, 80.6) | (17.2, 51.6) | (16.6, 49.0) | (10.2, 76.2) | (12.5, 93.3) | ||
TH2 | 11.7 | 10.8 | 10.1 | 10.3 | 9.5 | 11.7 | 10.6 | 10.9 | 0.12 |
(5.4, 47.8) | (6.8, 52.5) | (2.4, 93.7) | (2.2, 89.8) | (6.5, 21.4) | (7.6, 88.4) | (6.7, 82.8) | (3.5, 34.8) | ||
TH17 | 28.1 | 22.8 | 22.6 | 27.6 | 20.7 | 24.5 | 22.4 | 33.1 | 0.24 |
(13.0, 79.2) | (12.7, 48.9) | (13.5, 62.5) | (8.6, 74.6) | (11.2, 47.8) | (15.4, 53.9) | (8.9, 40.1) | (14.8, 68.5) | ||
Innate | 49.3 | 31.0 | 28.4 | 33.3 | 31.0 | 33.6 | 27.0 | 37.8 | 0.001 |
(19.1, 74.8) | (15.5, 54.9) | (11.7, 54.4) | (18.1, 71.2) | (17.0, 53.1) | (17.4, 61.6) | (16.2, 58.5) | (18.2, 63.8) | ||
Regulatory | 31.1 | 23.0 | 21.0 | 23.1 | 19.9 | 32.2 | 21.1 | 19.9 | 0.010 |
(13.0, 75.6) | (10.6, 100.0) | (7.5, 100.0) | (3.5, 82.1) | (15.7, 55.1) | (14.6, 75.1) | (11.6, 76.8) | (15.4, 69.5) |